Systemic sclerosis & Raynaud's
Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial
Authors' conclusion
Co-administration of PPI or HRB can significantly reduce the bioavailability of MMF in patients with SSc.
Study context
- Population
- Systemic sclerosis (SSc) patients on a stable dose of mycophenolate mofetil (MMF) (1.5–3 g)
- Participants
- 20 patients
- Comparison
- MMF alone vs MMF plus ranitidine vs MMF plus esomeprazole
- MMF alonen = 20reference
- Ranitidinen = 20
- Esomeprazolen = 20
- Primary endpoint
- 12-hour AUC of mycophenolic acid (MPA) levels
- Follow-up
- End of each month
Methodological detailssequential crossover
- Sequential crossover
Primary result
As reported in the abstract
Mean 12-hour AUC of MPA, reduction vs MMF alone
Mean difference
22.28 μg h ml-1
Esomeprazole · 32.7% reduction in mean AUC Mycophenolic Acid (MPA)
Mean difference
14.93 μg h ml-1
Ranitidine · 21.97% reduction in MPA AUC
Further findings
Total gastrointestinal (GI) score · end of each month
- Addition of ranitidine or esomeprazole resulted in significant reduction in total GI score
Original publication
Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial. Semin Arthritis Rheum. Published 28 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →